NCCN Receives $2 Million Grant from Pfizer

Funding will support innovative cancer research JENKINTOWN, Pa., September 5, 2006 — The National Comprehensive Cancer Network (NCCN) and Pfizer, Inc., have entered into a collaboration to conduct research on the oral multikinase inhibitor sunitinib (Sutent), a drug currently approved for advanced renal cell carcinoma and gastrointestinal stromal tumors. Sutent is being studied in a broad range of solid tumors. “NCCN’s goal is to improve the quality, effectiveness and efficiency of oncology prac...
Source: National Comprehensive Cancer Network Oncology Research Program - Category: Cancer & Oncology Source Type: news